New Drug Reviews

Dabigatran (Pradaxa) for Prevention of Stroke in Atrial Fibrillation


Am Fam Physician. 2011 Dec 15;84(12):1397-1398.

Dabigatran (Pradaxa) is an orally administered direct thrombin inhibitor labeled for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Unlike warfarin (Coumadin), it does not induce anticoagulation through depletion of clotting factors, but through an immediate effect on thrombin, the last step in the coagulation cascade that causes clot formation.

 Enlarge     Print

DrugDosageDose formCost of full course*

Dabigatran (Pradaxa)

150 mg twice daily; 75 mg twice daily in patients with impaired renal function

75- and 150-mg capsules

$246 for 60 150-mg capsules

*—Estimated retail price of one month's treatment based on information obtained at (accessed October 25, 2010).

DrugDosageDose formCost of full course*

Dabigatran (Pradaxa)

150 mg twice daily; 75 mg twice daily in patients with impaired renal function

75- and 150-mg capsules

$246 for 60 150-mg capsules

*—Estimated retail price of one month's treatment based on information obtained at (accessed October 25, 2010).


Dabigatran increases the risk of minor and major bleeding. In a randomized controlled trial of dabigatran compared with dose-adjusted warfarin (International Normalized Ratio of 2.0 to 3.0) in more than 18,000 patients with atrial fibrillation, life-threatening bleeding and intracranial hemorrhage occurred less often with dabigatran, with one fewer patient experiencing an intracranial hemorrhage for every 117 patients treated with dabigatran instead of warfarin (number needed to treat [NNT] = 117; 95% confidence interval [CI], 82 to 201).1 Although gastrointestinal bleeding occurs more often with dabigatran, the incidence of minor bleeding is lower (NNT = 37; 95% CI, 23 to 99).1 Unlike warfarin, dabigatran lacks significant drug interactions. However, the concurrent use of antiplatelet agents, heparin, or long-term nonsteroidal anti-inflammatory drugs may increase the risk of bleeding. There is no reversal agent for dabigatran. It is renally eliminated, and the dosage must be reduced in patients with a creatinine clearance of less than 30 mL per minute per 1.73 m2 (0.50 mL per second per m2).2 Dabigatran has not been studied in children or in pregnant or breastfeeding women. It is a U.S Food and Drug Administration pregnancy category C drug.


In clinical trials, more patients receiving dabigatran withdrew because of adverse effects compared with those receiving warfarin. Dabigatran causes dyspepsia and gastritis symptoms in about one-third of patients.2


Dabigatran has been compared with enoxaparin (Lovenox) and warfarin in randomized controlled trials. In a study of 18,000 patients with atrial fibrillation, those who received dabigatran had significantly fewer ischemic strokes than those who received warfarin for a median of two years (NNT = 91; 95% CI, 59 to 194).1 Dabigatran has been studied for surgery prophylaxis (versus enoxaparin) and for the treatment of deep venous thrombosis and pulmonary embolism (versus warfarin), but it is not labeled for these uses.35


A one-month supply of 150-mg dabigatran capsules costs approximately $246; a one-month supply of generic warfarin costs approximately $15.6 The lack of laboratory monitoring or office visits for dose titration may partially offset this difference.


Dabigatran produces an effect on coagulation in 30 to 90 minutes, has a predictable response, does not require routine laboratory monitoring, and does not have the drug and food interactions that can be problematic with warfarin therapy. Patient compliance with twice-daily dosing must be stressed. The dose of dabigatran is fixed and does not require titration when therapy is initiated or discontinued.

Bottom Line

Dabigatran is superior to warfarin for stroke prevention in patients with atrial fibrillation, with similar rates of major bleeding. Because it does not require laboratory monitoring, dabigatran therapy is less complicated than warfarin therapy, but it costs significantly more.

Address correspondence to Jennifer L. Strohecker, PharmD, BCPS, at Reprints are not available from the author.

Author disclosure: No relevant financial affiliations to disclose.


show all references

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010;363(19):1877]. N Engl J Med. 2009;361(12):1139–1151....

2. Pradaxa [prescribing information]. Ridgefield, Conn.: Boehringer Ingelheim; 2011. Accessed September 17, 2011.

3. Eriksson BI, Dahl OE, Rosencher N, et al.; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–2185.

4. Eriksson BI, Dahl OE, Rosencher N, et al.; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial [published correction appears in Lancet. 2007;370(9604):2004]. Lancet. 2007;370(9591):949–956.

5. Schulman S, Kearon C, Kakkar AK, et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352.

6. Accessed October 25, 2011.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

The series coordinator for AFP is Allen F. Shaughnessy, PharmD, Tufts University Family Medicine Residency Program at Cambridge Health Alliance, Malden, Mass.

A collection of STEPS published in AFP is available at



Copyright © 2011 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

More in AFP

Editor's Collections

Related Content

More in Pubmed


Sep 2021

Access the latest issue of American Family Physician

Read the Issue

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article